ArticleRespirology case reports2025
A Case of Steroid-Dependent Immune Checkpoint Inhibitor Pneumonitis Treated With Subcutaneous Tocilizumab.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Case of Steroid-Dependent Immune Checkpoint Inhibitor Pneumonitis Treated With Subcutaneous Tocilizumab.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 57-year-old male with a history of urothelial cancer status post neoadjuvant cisplatin and gemcitabine, cystoprostatectomy and adjuvant nivolumab developed immune checkpoint inhibitor pneumonitis (ICI-p) following nivolumab treatment. He was treated with steroids but developed recurrent ICI-p during multiple steroid tapers. Given accumulating side effects from prolonged steroid treatment and the desire to minimise frequent visits to the clinic and infusion center, tocilizumab, which can be administered subcutaneously at home, was considered for steroid-dependent pneumonitis. Ultimately, he received intravenous followed by subcutaneous tocilizumab, and after a few months of treatment, he was weaned off steroids with sustained resolution of ICI-p, had improvement in steroid-related side effects, and had no progression or recurrence of his underlying bladder cancer. To our knowledge, this is the first case of subcutaneous tocilizumab being utilised for steroid-dependent ICI-p.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.